drugset / Trial / NCT02317471
Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.
Timeline
- Start
- 2014-11
- Primary completion
- 2017-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vitespen | Vaccine | 25 ug | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 200 mg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 400 mg | Intravenous |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Background | S-1 | Small molecule | 40 mg | — |
| Background | S-1 | Small molecule | 60 mg | — |